|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:2014
gptkb:FDA
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:brand
|
gptkb:Esbriet
|
|
gptkbp:casnumber
|
53179-13-8
|
|
gptkbp:chemical_formula
|
C19 H17 N3 O2
|
|
gptkbp:clinical_trial
|
gptkb:ASCEND_trial
gptkb:CAPACITY_trials
Phase III
|
|
gptkbp:clinical_use
|
treatment of lung fibrosis
|
|
gptkbp:composed_by
|
gptkb:chemical_compound
|
|
gptkbp:contraindication
|
severe liver impairment
hypersensitivity to pirfenidone
|
|
gptkbp:developed_by
|
gptkb:Inter_Mune
|
|
gptkbp:discovery_year
|
1970s
|
|
gptkbp:dosage_form
|
oral tablet
oral capsule
|
|
gptkbp:duration
|
long-term therapy
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
gptkb:tablet
gptkb:capsule
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Pirfenidone
|
|
gptkbp:interacts_with
|
gptkb:warfarin
other antifibrotic agents
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_a_guide_for
|
gptkb:Japanese_Respiratory_Society
gptkb:European_Respiratory_Society
gptkb:American_Thoracic_Society
|
|
gptkbp:is_monitored_by
|
pulmonary function tests
liver function tests
|
|
gptkbp:lifespan
|
approximately 24 hours
|
|
gptkbp:marketed_as
|
gptkb:Esbriet
|
|
gptkbp:mechanism_of_action
|
anti-fibrotic
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:origin
|
natural product
|
|
gptkbp:patient_population
|
adults
|
|
gptkbp:pharmacokinetics
|
absorption
|
|
gptkbp:provides_guidance_on
|
recommended for IPF
|
|
gptkbp:research_areas
|
fibrosis
pulmonary medicine
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:side_effect
|
gptkb:anemia
fatigue
nausea
diarrhea
rash
skin reactions
thrombocytopenia
elevated liver enzymes
liver function abnormalities
|
|
gptkbp:used_for
|
gptkb:idiopathic_pulmonary_fibrosis
|
|
gptkbp:bfsParent
|
gptkb:idiopathic_pulmonary_fibrosis
|
|
gptkbp:bfsLayer
|
7
|